Advancing Bayesian Methods in Clinical Trials
Explore how Bayesian statistical methods are reshaping clinical trial design. Learn how FDA support, adaptive…
CertaraMarch 9, 2026
Pharmacovigilance aggregate reporting in China
Learn best practices for China pharmacovigilance aggregate reporting, with expert support and regulatory guidance insights.
CertaraMarch 6, 2026
DIA RSIDM 2026: From doing digital to being data-driven
JTVCdGVhbV9qdW1wX2xpc3QlNUQ= March 5, 2026 The atmosphere at this year's DIA RSIDM conference was defined by…
CertaraMarch 5, 2026
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer
This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…
Danielle PillsburyMarch 4, 2026
Document Quality and Management
Ensure submission readiness with Certara’s Document Quality services. We deliver compliant, inspection-ready regulatory documents that…
CertaraFebruary 27, 2026
Safety & Pharmacovigilance Writing
Expertly delivering Safety & Pharmacovigilance Writing services, including Aggregate Safety Reports, Risk Management Plans, and…
CertaraFebruary 27, 2026
On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…
CertaraFebruary 26, 2026
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth…
CertaraFebruary 26, 2026
Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)
Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…
CertaraFebruary 13, 2026
